Autopsy report · NCT03013946

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

“insufficient accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 7 years before it stopped.
• 121 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

AIO-Studien-gGmbH

Sponsor type

University, hospital or other

Conditions

Renal Cell Carcinoma, Metastatic; Renal Cell Cancer, Recurrent

Interventions

Concomitant coaching

Participants

121

Sites

22

Countries

Germany

Trials that died the same way

• Antiretroviral Improvement Among Medicaid Enrollees
  “Insufficient rate of accrual” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (89% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (86% match in meaning)
• OD-PHOENIX in Talus Osteochondral Lesion
  “Low accrual rate” (85% match in meaning)
• Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
  “Insufficient accrual” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.